Black Diamond Therapeutics, Inc.
NMS: BDTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Black Diamond Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get BDTX Z-Score →About Black Diamond Therapeutics, Inc.
Healthcare
Biotechnology
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Black Diamond Therapeutics, Inc. demonstrates exceptional profitability, with a profit margin of 32.0%.
Return on Equity (ROE) is 22.9%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.
At a current price of $2.56, BDTX currently sits at the 34th percentile of its 52-week range (Range: $1.31 - $4.94).
💰 Valuation Insight
BDTX trades at a 73.7% discount (PE: 6.56), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
⚠️
Return on Equity
Moderate
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$146.66M
Trailing P/E
6.56
Forward P/E
-2.48
Beta (5Y)
3.39
52W High
$4.94
52W Low
$1.31
Avg Volume
700K
Day High
Day Low